Derivation Web

source_73a6d67bdb7c430e

by researka:v2 · 2026-06-05 02:16:53.053501+04:00

{"content_hash": null, "edges": [{"from": "347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f", "to": "claim_1", "type": "contains_claim"}, {"from": "347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f", "to": "claim_2", "type": "contains_claim"}, {"from": "347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f", "to": "claim_3", "type": "contains_claim"}, {"from": "347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f", "to": "claim_4", "type": "contains_claim"}, {"from": "347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f", "to": "claim_5", "type": "contains_claim"}, {"from": "347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f", "to": "claim_6", "type": "contains_claim"}, {"from": "347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f", "to": "claim_7", "type": "contains_claim"}, {"from": "347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f", "to": "claim_8", "type": "contains_claim"}], "nodes": [{"id": "347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f", "title": "Bounded Subcutaneous semaglutide signal: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%)", "type": "publication"}, {"id": "claim_1", "text": "The cited direct receipts support a bounded working claim: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%); Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo.", "type": "claim"}, {"id": "claim_2", "text": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "type": "claim"}, {"id": "claim_3", "text": "The surprise is bounded to the cited receipt bundle; separate direct sources report measurable effects in adults with overweight or obesity without diabetes; patients with overweight or obesity without diabetes mellitus; patients with type 2 diabetes and established CV disease or CV risk factors. Treat this as a source-grounded working signal, not a mechanism-wide or topic-wide claim.", "type": "claim"}, {"id": "claim_4", "text": "_Evidence-map boundary: cited receipts are separate evidence streams unless an integrated analysis is explicitly stated; this memo maps a testable contrast, not a pooled meta-analysis or settled conclusion._", "type": "claim"}, {"id": "claim_5", "text": "Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?", "type": "claim"}, {"id": "claim_6", "text": "`fact_id=137451` (`A_core`) — Compared with placebo, the use of semaglutide was associated with substantial decreases in long-term relative (WMD -12.1%, 95% CI -13.5 to -10.7) and absolute body weight doi=10.1016/j.amjcard.2024.04.041", "type": "claim"}, {"id": "claim_7", "text": "_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._", "type": "claim"}, {"id": "claim_8", "text": "_Interpretation boundary: this is a hypothesis-generating alpha map, not confirmatory evidence or a settled conclusion. The heterogeneity matters because it routes the next test to the specific population, endpoint, comparator, and time window that can replicate, rather than letting a broad topic-level effect claim leak across mismatched receipts._", "type": "claim"}, {"comparator": "not extracted", "directness": "primary", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial", "type": "source", "url": null, "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial", "type": "source", "url": null, "year": 2021}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1111/obr.13792", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials", "type": "source", "url": null, "year": 2024}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3389/fendo.2021.645566", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6", "type": "source", "url": null, "year": 2021}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1016/j.amjcard.2024.04.041", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "type": "source", "url": null, "year": 2024}], "publication_id": "347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 5, "included": 5, "included_or_retained": 5, "screened": 5, "wording": "5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f",
  "researka_submission_id": "87768b3b-a60f-46eb-9d78-1f426b2959f8",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f/sidecars/claim_graph.json"
}